全文获取类型
收费全文 | 1897篇 |
免费 | 239篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 62篇 |
妇产科学 | 69篇 |
基础医学 | 299篇 |
口腔科学 | 10篇 |
临床医学 | 227篇 |
内科学 | 438篇 |
皮肤病学 | 38篇 |
神经病学 | 186篇 |
特种医学 | 144篇 |
外科学 | 240篇 |
综合类 | 34篇 |
现状与发展 | 1篇 |
预防医学 | 142篇 |
眼科学 | 12篇 |
药学 | 113篇 |
肿瘤学 | 121篇 |
出版年
2023年 | 31篇 |
2022年 | 13篇 |
2021年 | 26篇 |
2020年 | 32篇 |
2019年 | 35篇 |
2018年 | 48篇 |
2017年 | 37篇 |
2016年 | 46篇 |
2015年 | 46篇 |
2014年 | 54篇 |
2013年 | 71篇 |
2012年 | 100篇 |
2011年 | 79篇 |
2010年 | 60篇 |
2009年 | 58篇 |
2008年 | 79篇 |
2007年 | 86篇 |
2006年 | 77篇 |
2005年 | 76篇 |
2004年 | 81篇 |
2003年 | 59篇 |
2002年 | 59篇 |
2001年 | 51篇 |
2000年 | 47篇 |
1999年 | 46篇 |
1998年 | 30篇 |
1997年 | 20篇 |
1996年 | 19篇 |
1995年 | 17篇 |
1994年 | 35篇 |
1993年 | 25篇 |
1992年 | 36篇 |
1991年 | 34篇 |
1990年 | 38篇 |
1989年 | 42篇 |
1988年 | 32篇 |
1987年 | 37篇 |
1986年 | 27篇 |
1985年 | 35篇 |
1984年 | 33篇 |
1983年 | 20篇 |
1982年 | 17篇 |
1981年 | 21篇 |
1980年 | 19篇 |
1979年 | 17篇 |
1978年 | 17篇 |
1977年 | 15篇 |
1976年 | 15篇 |
1975年 | 23篇 |
1973年 | 15篇 |
排序方式: 共有2145条查询结果,搜索用时 15 毫秒
61.
62.
63.
Horne BD Muhlestein JB May HT Carlquist JF Lappé DL Bair TL Anderson JL;Intermountain Heart Collaborative Study Group 《The American journal of cardiology》2012,109(11):1558-1562
Previously we discovered that routine periodic fasting was associated with a lower prevalence of coronary artery disease (CAD). Other studies have shown that fasting increases longevity in animals. A hypothesis-generating analysis suggested that fasting may also associate with diabetes. This study prospectively tested whether routine periodic fasting is associated with diabetes mellitus (DM). Patients (n = 200) undergoing coronary angiography were surveyed for routine fasting behavior before their procedure. DM diagnosis was based on physician reports of current and historical clinical and medication data. Secondary end points included CAD (physician reported for ≥ 1 lesion of ≥ 70% stenosis), glucose, and body mass index (BMI). Meta-analyses were performed by evaluation of these patients and 448 patients from a previous study. DM was present in 10.3% of patients who fasted routinely and 22.0% of those who do not fast (odds ratio [OR] 0.41, 95% confidence interval [CI] 0.17 to 0.99, p = 0.042). CAD was found in 63.2% of fasting and 75.0% of nonfasting patients (OR 0.42, CI 0.21 to 0.84, p = 0.014), and in nondiabetics this CAD association was similar (OR 0.38, CI 0.16 to 0.89, p = 0.025). Meta-analysis showed modest differences for fasters versus nonfasters in glucose concentrations (108 ± 36 vs 115 ± 46 mg/dl, p = 0.047) and BMI (27.9 ± 5.3 vs 29.0 ± 5.8 kg/m(2), p = 0.044). In conclusion, prospective hypothesis testing showed that routine periodic fasting was associated with a lower prevalence of DM in patients undergoing coronary angiography. A reported fasting association with a lower CAD risk was also validated and fasting associations with lower glucose and BMI were found. 相似文献
64.
Minder CM Blaha MJ Horne A Michos ED Kaul S Blumenthal RS 《The American journal of medicine》2012,125(5):440-446
Three-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, commonly known as statins, are widely available, inexpensive, and represent a potent therapy for treating elevated cholesterol. Current national guidelines put forth by the Adult Treatment Panel III recommend statins as part of a comprehensive primary prevention strategy for patients with elevated low-density lipoprotein cholesterol at increased risk for developing coronary heart disease within 10 years. Lack of a clear-cut mortality benefit in primary prevention has caused some to question the use of statins for patients without known coronary heart disease. On review of the literature, we conclude that current data support only a modest mortality benefit for statin primary prevention when assessed in the short term (<5 years). Of note, statin primary prevention results in a significant decrease in cardiovascular morbidity over the short and long term and a trend toward increased reduction in mortality over the long term. When appraised together, these data provide compelling evidence to support the use of statins for primary prevention in patients with risk factors for developing coronary heart disease over the next 10 years. 相似文献
65.
66.
67.
Lauren C. Nisbet Stephanie R. Yiallourou Gillian M. Nixon Sarah N. Biggs Margot J. Davey John Trinder Lisa M. Walter Rosemary S.C. Horne 《Sleep medicine》2013,14(11):1123-1131
Background
Surges in heart rate (HR) and blood pressure (BP) at apnea termination contribute to the hypertension seen in obstructive sleep apnea (OSA). Because childhood OSA prevalence peaks in the preschool years, we aimed to characterize the cardiovascular response to obstructive events in preschool-aged children.Methods
Clinically referred children aged 3–5 years were grouped by obstructive apnea–hypopnea index (OAHI) into the following: primary snoring (PS) (OAHI ? 1 event/h [n = 21]), mild OSA (OAHI > 1– ? 5 [n = 32]), and moderate to severe (MS) OSA (OAHI > 5 [n = 28]). Beat-to-beat pulse transit time (PTT), an inverse continuous indicator of BP changes, and HR were averaged during the two halves (early and late) and during the peak after (post) each obstructive event and were expressed as percentage change from late- to post-event.Results
We analyzed 422 events consisting of 55 apneas and 367 hypopneas. A significant post-event increase in HR and fall in PTT occurred in all severity groups (P < .05 for all). A greater response was associated with OSA, nonrapid eye movement sleep (NREM), cortical arousal, hypopneas, and oxygen desaturation (P < .05 for all).Conclusions
Obstructive events elicit acute cardiovascular changes in preschool children. Such circulatory perturbations have been implicated in the development of hypertension, and our findings complement previous studies to suggest a cumulative impact of snoring on the cardiovascular system from childhood into adulthood. 相似文献68.
Nicola Dalbeth Bregina Pool Angela Stewart Anne Horne Meaghan E. House Jillian Cornish Ian R. Reid 《Calcified tissue international》2013,92(1):1-5
The conventional model that bisphosphonates bind to the bone surface and inhibit mature osteoclasts does not convincingly explain the prolonged duration of action of zoledronate. We hypothesized that zoledronate on the bone surface adjacent to marrow cells impairs osteoclastogenesis, contributing to sustained inhibition of resorption. In this case, numbers of circulating preosteoclasts may be reduced after zoledronate treatment. This study assessed this possibility in subjects from a clinical trial. Twenty-two osteopenic women participating in a randomized, controlled trial comparing zoledronate 5 mg with placebo were recruited, 18 months after administration of study drug. Peripheral blood mononuclear cells were analyzed for the presence of osteoclast precursors using flow cytometry for preosteoclast markers and the ability to form osteoclast-like cells in culture with RANKL and M-CSF. There was no difference in the percentage of CD14+/CD11b+ cells in peripheral blood between the two groups. The numbers of TRAP+ multinucleated cells in cultures in the absence of RANKL and M-CSF were very low in both groups, but a significantly higher number of these cells was observed in the zoledronate group compared with the placebo group (p = 0.01). The number of TRAP+ multinucleated cells and resorption pits following culture with RANKL and M-CSF did not differ between the two groups. Serum P1NP was reduced 53 % at 18 months in the zoledronate group but unchanged in the placebo group. These results do not support the hypothesis that the inhibitory action of zoledronate contributes to its prolonged action on preosteoclasts within bone marrow. 相似文献
69.
Mark J. Bolland Andrew Grey Anne M. Horne Ian R. Reid 《Calcified tissue international》2013,93(2):133-136
Recent preclinical studies suggest that osteoblasts are able to induce testosterone production by the testis, a process mediated by osteocalcin. Bisphosphonates substantially reduce osteocalcin levels. If osteocalcin is an important regulator of testosterone levels in adult men, it would be expected that the substantial reductions in osteocalcin induced by zoledronate would impact negatively on testosterone levels. Previously, we carried out a 2-year randomized, controlled trial of annual 4 mg zoledronate in 43 HIV-infected men. To explore the relationship between osteocalcin and testosterone further, we measured serum testosterone at baseline, 3 months, and 2 years; luteinizing hormone at 3 months and 2 years; and total osteocalcin at 2 years in 28 trial participants with available blood samples. At 2 years, total osteocalcin was 39 % lower in the zoledronate group than the placebo group (zoledronate mean 10.1 [SD 3.0] μg/L, placebo 16.5 [SD 4.9] μg/L, P = 0.003). Despite these substantial differences in osteocalcin levels, testosterone levels did not change over time in either group and there were no between-group differences over time, P = 0.4 (mean change at 2 years [adjusted for baseline levels] in zoledronate group ?0.4 nmol/L, 95 % CI ?2.5 to 1.6; placebo group 0.4 nmol/L, 95 % CI ?1.6 to 2.5). Luteinizing hormone was within the normal range and did not differ between the groups at either 3 months or 2 years. Thus, the absence of a change in testosterone despite a substantial reduction in osteocalcin following zoledronate treatment argues against a biologically significant role for osteocalcin in the regulation of testosterone in adult men. This provides reassurance that men receiving potent antiresorptive drugs are not at risk of iatrogenic hypogonadism. 相似文献
70.